FINNENCE ▪ THE WIRE FILE
THE WIRE · № 78713
SEC Filing■ Unclear/unknown
CRWD filed 4 on 2026-10-13
KINDSEC Filing
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Form 4 discloses insider transactions; direction depends on whether it was a buy or sale, which the text does not specify.
Routine insider filing with unspecified transaction
CATALYST TO WATCH
Details of the transaction in the filing
MAIN RISK
Could signal insider selling if a disposal
FULL DISPATCH
CRWD (CIK 0001778564) filed a 4 on 2026-10-13.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTCrowdStrike · CRWD
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors — GlaxoSmithKline2026-10-13 12:00 UTC
New Phase 3 trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors — GlaxoSmithKline2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.2026-10-13 12:00 UTC
New Phase 3 trial: Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease — Beijing VDJBio Co., LTD.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
New Phase 3 trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy — SystImmune Inc.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
New Phase 3 trial: A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) — Takeda2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
New Phase 3 trial: Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia — Il-Yang Pharm. Co., Ltd.2026-10-13 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
New Phase 3 trial: To Evaluate HU-045 With Moderate to Severe Glabellar Lines — Huons Biopharma2026-10-13 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.